Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03648541 · ClinicalTrials.gov registry record · Phase 2
BI 655130 Long-term Treatment in Patients With moderate-to Severe Ulcerative Colitis
A Phase 2 study, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 2
- Development phase
- 79
- Enrollment target
NCT03648541 is a Phase 2 study that has completed, run by Boehringer Ingelheim. The registered enrollment target is 79 participants.
The verdict
NCT03648541, a Phase 2 study, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 79 participants
- Enrollment target
Study Summary
To evaluate the long-term safety of BI 655130 (SPESOLIMAB) in patients with moderate to severely active ulcerative colitis, who have completed treatment in previous trials To evaluate the long-term efficacy of BI 655130 (SPESOLIMAB) in patients with moderate to severely active ulcerative colitis, who have completed treatment in previous trials
Interventions
- DRUG Spesolimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 79 participants |
| Start Date | 2018-10-29 |
| Est. Completion | 2023-05-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03648541
The ClinicalTrials.gov registry entry for NCT03648541 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 79 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Spesolimab is the first listed.
NCT03648541 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03648541 about?
NCT03648541 is a clinical study titled "BI 655130 Long-term Treatment in Patients With moderate-to Severe Ulcerative Colitis". To evaluate the long-term safety of BI 655130 (SPESOLIMAB) in patients with moderate to severely active ulcerative colitis, who have completed treatment in previous trials To evaluate the long-term efficacy of BI 655130 (SPESOLIMAB) in patients with moderate to severely active ulcerative colitis, w...
What is the current status of trial NCT03648541?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 79 participants. The study started on 2018-10-29. Estimated completion is 2023-05-03.
What interventions are being tested in trial NCT03648541?
The interventions under investigation include: Spesolimab (DRUG).
Who is sponsoring clinical trial NCT03648541?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.